PHASE II STUDY OF DOCETAXEL AND OXALIPLATIN IN METASTATIC TRANSITIONAL CELL CANCER TCC ; OF THE UROTHELIAL TRACT PROTOCOL #04-055 4-6-05 Results of the Phase I II trial of gemcitabine cisplatin paclitaxel in advanced TCC were also recently reported by Bellmunt et al. The Phase II regimen consisted of cisplatin 70 mg m2 on day 1; paclitaxel 80 mg m2 over 1 hour on days 1 and 8; and gemcitabine 1000 mg m2 on days 1 and 8 of a day cycle. In the 58 evaluable patients, the overall RR was 78% 95% CI 60 to 98% ; , with a CR rate of 28%. Median survival for the Phase I component was over 20 months. Ifosfamide Paclitaxel Cisplatin ITP ; 59 ; Bajorin and his colleagues at Memorial Sloan-Kettering Cancer Center MSKCC ; , developed ITP for the treatment of patients with advanced TCC. The regimen is comprised of cisplatin 70 mg m2 on day 1; paclitaxel 200 mg m2 over 3 hours on day 1; and ifosfamide 1.5g m2 d for 3 days days 1-3 ; on a q 21 day schedule. Results from the first 44 patients, reported an overall RR of 68% 95% CI 52 to 81% ; . At 28 months of follow-up, the median survival was 20 months. All the patients required growth factor support, and the major toxicities were hematologic, renal, and neuropathic. Sequential Doxorubicin Gemcitabine AG ; , followed by ITP 60 ; This is the companion trial to ITP, also developed by investigators at MSKCC. In the Phase I setting, doxorubicin 50 mg m2 and gemcitabine 2000 mg m2 were administered on day 1, every 2 weeks for a total of 6 cycles. G-CSF support was necessary to maintain the delivery of chemotherapy on schedule. This was followed by the 21-day ITP regimen for a total of 4 cycles. In the 15 patients treated, the overall RR was 64%. The phase II component of this trial is ongoing. Docetaxel and Oxaliplatin Multiple cytotoxic agents and multiple combinations have activity in TCC. The frontline regimens in this disease include Gemcitabine-Cisplatin, MVAC, and Carboplatin-Taxol. Despite its exquisite chemosensitivity, bladder cancer frequently relapses, and the impact of chemotherapy on survival is minimal. Furthermore, there are few salvage regimens available for patients with recurrent disease. Single agent docetaxel has been reported to have response rates of 15 to 20% in the salvage setting, and oxaliplatin may also elicit responses in cisplatin-resistant patients. Additionally, the combination has non-overlapping toxicities except for neuropathy ; , and maybe particularly appropriate for elderly patients with impaired renal function. Hence the combination of docetaxel and oxaliplatin may be useful in recurrent incurable TCC, and if active, may also have a role as a frontline regimen in patients with either impaired marrow reserve or abnormal renal function. 1.2 Information on study drugs.
Boyd et al. 2001 ; and increasing expression of the norepinephrine transporter using cisplatin Armour et al. 1997 ; and combinations of interferon-gamma, tumor necrosis factor-alpha, and retinoic acid Montaldo et al. 1996 ; . A clinical treatment protocol, based on such studies, has been approved at the NIH, Bethesda, MD, USA, but has been on hold due to institutional funding and staffing limitations. At the Children's Hospital of Philadelphia, John Maris reports similar problems for their clinical trials to treat neuroblastoma, which together with high costs and lack of appropriate commercial sources of 131I-MIBG constrains availability of the therapy to only a few of many eligible pediatric patients. Future progress in these and other clinical therapeutics trials requires encouragement of a multidisciplinary team approach at the institutional level with an adequate level of support to ensure that all eligible patients have access to new experimental treatments as these become available. Identification of a suitable vendor at the US national level would be useful for trials involving 131I-MIBG. Because neuroendocrine tumors, including pheochromocytomas, express a number of subtypes of somatostatin receptors, administration of analogs of somatostatin have been proposed as another treatment for malignant pheochromocytoma Wiseman & Kvols 1995 ; . Although some initial small scale studies have indicated reduction in tumor catecholamine production Invitti et al. 1993 ; or symptomatic improvement Kopf et al. 1997 ; , this has not been confirmed by other groups Lamarre-Cliche et al. 2002 ; and may only be useful in subgroups of tumors with membrane-associated somatostatin type 3 receptors Mundschenk et al. 2003 ; . Nevertheless, as discussed at the workshop by Hendrik Lehnert, combined treatment with novel somatostatin analogs and 131I-MIBG may confer additional benefit over 131I-MIBG treatment alone. Development of other more effective targeted therapies for malignant pheochromocytoma can be expected to take advantage of the wealth of new drugs being developed in response to advances in the elucidation of pathways responsible for other cancers. Use of DNA microarray and proteomics technologies for understanding the pathways contributing to benign and malignant pheochromocytoma should be useful for guiding the choice of the most appropriate of these agents for future therapeutic trials. Already there are suggestions of possible targets in malignant pheochromocytoma for new classes of anticancer drugs being developed in response to improved understanding of pathways involved in other malignancies Table 3 ; . Over-expression of HSP90 in malignant pheochromocytomas Boltze et al. 2003 ; , in particular, indicates one promising therapeutic target for a new class of anticancer drugs being developed to inhibit this protein Maloney & Workman 2002 ; . HSP90 is now understood to function as a molecular chaperone that maintains the folding and conformation of proteins crucial in regulating the balance between degradation and synthesis of cell signaling proteins, including many involved in multiple oncogenic pathways. Such proteins include the human telomerase reverse transcriptase, which also shows increased expression in malignant pheochromocytoma Boltze et al. 2003, Elder et al. 2003 ; . Should HSP90 be proven to be involved in the transition from a benign to malignant pheochromocytoma phenotype, then new inhibitors of the protein, such as 17-allylamino, 17-demethoxygeldamycin Sausville et al. 2003 ; , may be of value as treatments for the malignancy. Findings from several groups that malignant pheochromocytomas are characterized by increased expression of factors associated with angiogenesis Table 3 ; suggest other pathways that may respond to new anti-angiogenic drugs currently in development or approved by the Food and Drug Administration for specific types of cancer. Even with the advent of new therapeutic targets and drugs it remains likely that a combination of therapies will be required for effective treatment. Given the heterogenous nature of pheochromocytomas, it is also likely that for best therapeutic results, treatments may have to be tailored according to differences in underlying pathways. Developing such approaches will benefit from the opportunities available from the new genomic and proteomic methodologies and other developments associated with new drug discovery technologies, such as high throughput screening of drug candidates. The current unfolding of the NIH roadmap Zerhouni 2003 ; makes this a time of flux in research priorities and a movement towards future advances in medical research that will take advantage of the tremendous information available in the post-genome era. This is also a pivotal time-point to move forward from past and present methods and procedures for diagnosis, localization, and treatment of pheochromocytoma to research into novel methodologies based on the new pathways to discovery Table 4 ; . As outlined in the new roadmap, taking advantage of the new technologies available in the postgenome era is best undertaken by multidisciplinary research teams involving centers and individuals with the necessary expertise. Importantly, research about pheochromocytoma already includes such a platform, involving interactions among clinicians and investigators in diverse fields, including endocrinology, human genetics, clinical chemistry, radiology, nuclear medicine, surgery, pathology, and oncology. This already existing multidisciplinary platform can be broadened to further take advantage of new technologies and, due to the rare nature of the tumor, should also better bring together various.

Modular Collective Protection Equipment MCPE ; consists of a family of related end items from which modules can be chosen and combined to meet the unique demands of individual systems. These end items employ common parts and mountings and interchangeable connections and accessories to the greatest extent possible. MCPE provides collective overpressure to a wide variety of mobile shelters and vans. It uses the M48 NBC filter in the 100 cfm system and the M56 NBC filter in the others and cladribine.

Figure 5. Grizzly bear, being weighed in a sling. The sling will maintain dorsal recumbency and head and neck extension. It is suitable for short translocation flights. - To view this image in full size go to the IVIS website at ivis. The following two questions refer to the vignette below. A 48-year-old man with a dilated cardiomyopathy and chronic atrial fibrillation calls you at the office requesting a refill for warfarin. The nurse, whom he called in the anticoagulation clinic earlier, refused to give him a prescription because he had missed four appointments in the clinic. He has not had his prothrombin time checked in the past 2 months. He tells you he feels his "usual self" but has noted many bruises on his extremities without associated trauma. He "promises" to come to the office for his appointment in 3 weeks, but he has been "too busy" to come to the anticoagulation clinic. 37. The most appropriate response is and clofarabine. Ingn 241 shown to restore platinum sensitivity in preclinical studies data from preclinical studies of ingn 241 also were presented abstract #197 ; that evaluated the ability of ingn 241 to restore cisplatin sensitivity to ovarian cancer cells that are cisplatin-resistant. The clown is punctual. The clown has a pink Marge Simpson, a red nose and big clown shoes. Perfection. The clown berates our departing friend. The clown makes filthy balloon animals. The clown asks our friend to help him take off his shoes, as the clown's dogs are barking. Our friend senses something unsavory in this request, but assists with the clown shoe removal nonetheless. The music starts and the clown strips down to a pink g-string. Wow, those ain't potatoes. All is going according to plan until I catch the clown and the new love of my life honking each other's horns in the dining room. I hear the new love of my life say, "Nah, Jim's cool, he doesn't mind." An eyewitness, one of many, says: "Jim, what's he doing? I thought he was so nice." Me: "Tonsillectomy." At which point I tapped the new love of my life on the shoulder, said that I wasn't very cool, that I did mind, that I would have no more of this clowning around. We left. I hollered, puked red champagne punch, fell out, awoke, and hollered some more. I cried. I stomped. I slammed the door, too hurt, too humiliated to return. A day later I did. e and clofibrate.

44 Socinski MA, Schell MJ, Peterman A et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB IV non-small-cell lung cancer. J Clin Oncol 2002; 20: 13351343. Westeel V, Quoix E, Moro-Sibilot D et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 499506. von Plessen C, Bergman B, Andresen O et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006; 95: 966973. Belani CP, Barstis J, Perry MC et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21: 29332939. Belani CP, La Rocca RV, Rinaldi DA et al. A multicenter, phase III randomized trial for stage IIIB IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel. J Clin Oncol 2004; 22 14 suppl ; : 7017. 49 Belani CP, Barstis J, La Rocca RV et al. Meta-analysis of weekly paclitaxel as maintenance therapy for advanced non-small cell lung cancer patients following initial chemotherapy. Lung Cancer 2005; 49 suppl 2 ; : S33. 50 Fidias P, Dakhil SR, Lyss AP et al. Updated report of a phase III study of induction therapy with gemcitabine + carboplatin GC ; followed by either delayed vs. immediate second-line therapy with docetaxel D ; in advanced non-small cell lung cancer. J Clin Oncol 2006; 24 18 suppl ; : 7032. 51 Brodowicz T, Krzakowski M, Zwitter M et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 2006; 52: 155163. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 15891597. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study Iressa Survival Evaluation in Lung Cancer ; . Lancet 2005; 366: 15271537. Herbst RS, Giaccone G, Schiller J et al. Subset analyses of INTACT results for gefitinib ZD1839 ; when combined with platinum-based chemotherapy for advanced non-small cell lung cancer. Proc Soc Clin Oncol 2003; 22: 627 and clorazepate.